Discriminating among degenerative parkinsonisms using advanced 123I-ioflupane SPECT analyses

123I-ioflupane single photon emission computed tomography (SPECT) is a sensitive and well established imaging tool in Parkinson's disease (PD) and atypical parkinsonian syndromes (APS), yet a discrimination between PD and APS has been considered inconsistent at least based on visual inspection or simple region of interest analyses. We here reappraise this issue by applying advanced image analysis techniques to separate PD from the various APS. This study included 392 consecutive patients with degenerative parkinsonism undergoing 123I-ioflupane SPECT at our institution over the last decade: 306 PD, 24 multiple system atrophy (MSA), 32 progressive supranuclear palsy (PSP) and 30 corticobasal degeneration (CBD) patients. Data analysis included voxel-wise univariate statistical parametric mapping and multivariate pattern recognition using linear discriminant classifiers. MSA and PSP showed less ioflupane uptake in the head of caudate nucleus relative to PD and CBD, yet there was no difference between MSA and PSP. CBD had higher uptake in both putamen relative to PD, MSA and PSP. Classification was significant for PD versus APS (AUC 0.69, p < 0.05) and between APS subtypes (MSA vs CBD AUC 0.80, p < 0.05; MSA vs PSP AUC 0.69 p < 0.05; CBD vs PSP AUC 0.69 p < 0.05). Both striatal and extra-striatal regions contain classification information, yet the combination of both regions does not significantly improve classification accuracy. PD, MSA, PSP and CBD have distinct patterns of dopaminergic depletion on 123I-ioflupane SPECT. The high specificity of 84–90% for PD versus APS indicates that the classifier is particularly useful for confirming APS cases.

[1]  Claude Comtat,et al.  Striatal and extrastriatal dopamine transporter in cannabis and tobacco addiction: a high‐resolution PET study , 2012, Addiction biology.

[2]  Karl J. Friston.  Ten ironic rules for non-statistical reviewers , 2012, NeuroImage.

[3]  K P Bhatia,et al.  The role of DAT-SPECT in movement disorders , 2008, Journal of Neurology, Neurosurgery & Psychiatry.

[4]  C D Marsden,et al.  Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy , 1990, Annals of neurology.

[5]  Nooritawati Md Tahir,et al.  Parkinson Disease gait classification based on machine learning approach , 2012 .

[6]  I. Podreka,et al.  Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I]β-CIT and SPECT , 1997 .

[7]  Klaus Seppi,et al.  Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. , 2005, Brain : a journal of neurology.

[8]  John Seibyl,et al.  123-I Ioflupane SPECT measures of Parkinson disease progression in the Parkinson Progression Marker Initiative (PPMI) trial , 2013 .

[9]  H. Amthauer,et al.  Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration , 2006, Movement disorders : official journal of the Movement Disorder Society.

[10]  J. Booij,et al.  Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease , 2005, European Journal of Nuclear Medicine.

[11]  S. Haller,et al.  Distinct spatiotemporal patterns for disease duration and stage in Parkinson’s disease , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Shalini Jha,et al.  The diagnosis of Parkinson's disease. , 2003, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.

[13]  A. Alavi,et al.  MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. , 1987, AJR. American journal of roentgenology.

[14]  D. Brooks.  Can imaging separate multiple system atrophy from Parkinson's disease? , 2012, Movement disorders : official journal of the Movement Disorder Society.

[15]  V. Garibotto,et al.  Establishing On-Site Reference Values for 123I-FP-CIT SPECT (DaTSCAN®) Using a Cohort of Individuals with Non-Degenerative Conditions , 2016, Molecular Imaging and Biology.

[16]  Yoav Ben-Shlomo,et al.  The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. , 2002, Brain : a journal of neurology.

[17]  Sid Gilman,et al.  Second consensus statement on the diagnosis of multiple system atrophy , 2008 .

[18]  M. Canesi,et al.  123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy , 2003, Neurological Sciences.

[19]  W. Poewe,et al.  Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]β-CIT SPECT , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  Stephen M. Smith,et al.  Threshold-free cluster enhancement: Addressing problems of smoothing, threshold dependence and localisation in cluster inference , 2009, NeuroImage.

[21]  E. Tolosa,et al.  The diagnosis of Parkinson's disease , 2006, The Lancet Neurology.

[22]  S. Asenbaum,et al.  Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. , 1997, Journal of neural transmission. Supplementum.

[23]  D. Brooks.  Imaging dopamine transporters in Parkinson's disease. , 2010, Biomarkers in medicine.

[24]  N. Quinn,et al.  A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism , 2000, Neurology.

[25]  F. Carrillo,et al.  [Elaboration of the SPM template for the standardization of SPECT images with 123I-Ioflupane]. , 2013, Revista espanola de medicina nuclear e imagen molecular.

[26]  E. Tolosa,et al.  123I‐Ioflupane SPECT in the diagnosis of suspected psychogenic Parkinsonism , 2006, Movement disorders : official journal of the Movement Disorder Society.

[27]  Robert B. Innis,et al.  [123I]β‐CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy , 2001 .

[28]  J. Cummings,et al.  The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. , 2011, Brain : a journal of neurology.

[29]  D. Maraganore,et al.  The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease , 1999, Movement disorders : official journal of the Movement Disorder Society.

[30]  H. Zaidi,et al.  Regions of Interest–Based Discriminant Analysis of DaTSCAN SPECT and FDG-PET for the Classification of Dementia , 2013, Clinical nuclear medicine.

[31]  M. L. Fravolini,et al.  Diagnostic Accuracy of Parkinson Disease by Support Vector Machine (SVM) Analysis of 123I-FP-CIT Brain SPECT Data , 2014, Medicine.

[32]  V. Kaasinen,et al.  Normal dopamine transporter SPECT in neuropathologically confirmed corticobasal degeneration , 2013, Journal of Neurology.

[33]  S. Haller,et al.  Individual Detection of Patients with Parkinson Disease using Support Vector Machine Analysis of Diffusion Tensor Imaging Data: Initial Results , 2012, American Journal of Neuroradiology.

[34]  Klaus Seppi,et al.  Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysis. , 2006, Archives of neurology.

[35]  L. Deecke,et al.  [123I]β‐CIT spect in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration , 2000, Movement disorders : official journal of the Movement Disorder Society.

[36]  Brit Mollenhauer,et al.  The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: a critical assessment of 125 cases , 2011, Journal of Neurology.

[37]  Angela Spanu,et al.  Role of an artificial neural network classifier, a classification tree (ClT), to diagnose Parkinson's disease in early phase by using 123I-FP-CIT brain SPECT data , 2017 .

[38]  I Litvan,et al.  Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.

[39]  J. Booij,et al.  [123I]FP‐CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP‐lesioned monkeys , 1997, Synapse.

[40]  Lior Rokach,et al.  Pattern Classification Using Ensemble Methods , 2009, Series in Machine Perception and Artificial Intelligence.

[41]  F Segovia,et al.  Improved Parkinsonism diagnosis using a partial least squares based approach. , 2012, Medical physics.

[42]  Mark Hallett,et al.  Criteria for the diagnosis of corticobasal degeneration , 2013, Neurology.

[43]  H. Braak,et al.  Pathoanatomy of Parkinson’s disease , 2000, Journal of Neurology.

[44]  Jacques Darcourt,et al.  Extrastriatal binding of [123I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[45]  E. Tolosa,et al.  The diagnosis of Parkinson's disease , 2006, The Lancet Neurology.

[46]  M. Canesi,et al.  123 I-Ioflupane / SPECT binding to striatal dopamine transporter ( DAT ) uptake in patients with Parkinson ’ s disease , multiple system atrophy , and progressive supranuclear palsy , 2003 .

[47]  J. Johansson,et al.  Dorsal-to-Ventral Shift in Midbrain Dopaminergic Projections and Increased Thalamic/Raphe Serotonergic Function in Early Parkinson Disease , 2015, The Journal of Nuclear Medicine.

[48]  K. Lovblad,et al.  Differentiation between Parkinson disease and other forms of Parkinsonism using support vector machine analysis of susceptibility-weighted imaging (SWI): initial results , 2012, European Radiology.